Comprehensive analysis of NuMA variation in breast cancer.

Comprehensive analysis of NuMA variation in breast cancer. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Comprehensive analysis of NuMA variation in breast cancer. Abstract Text:

BACKGROUND: A recent genome wide case-control association study identified NuMA region on 11q13 as a candidate locus for breast cancer susceptibility. Specifically, the variant Ala794Gly was suggested to be associated with increased risk of breast cancer. METHODS: In order to evaluate the NuMa gene for breast cancer susceptibility, we have here screened the entire coding region and exon-intron boundaries of NuMa in 92 familial breast cancer patients and constructed haplotypes of the identified variants. Five missense variants were further screened in 341 breast cancer cases with a positive family history and 368 controls. We examined the frequency of Ala794Gly in an extensive series of familial (n = 910) and unselected (n = 884) breast cancer cases and controls (n = 906), with a high power to detect the suggested breast cancer risk. We also tested if the variant is associated with histopathologic features of breast tumors. RESULTS: Screening of NuMA resulted in identification of 11 exonic variants and 12 variants in introns or untranslated regions. Five missense variants that were further screened in breast cancer cases with a positive family history and controls, were each carried on a unique haplotype. None of the variants, or the haplotypes represented by them, was associated with breast cancer risk although due to low power in this analysis, very low risk alleles may go unrecognized. The NuMA Ala794Gly showed no difference in frequency in the unselected breast cancer case series or familial case series compared to control cases. Furthermore, Ala794Gly did not show any significant association with histopathologic characteristics of the tumors, though Ala794Gly was slightly more frequent among unselected cases with lymph node involvement. CONCLUSION: Our results do not support the role of NuMA variants as breast cancer susceptibility alleles.

Comprehensive analysis of NuMA variation in breast cancer. Publishing Authors By Initials

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Comprehensive analysis of NuMA variation in breast cancer. Journal Published:

PUBLICATION TYPE: Research Support, Non-U.S. Gov

Journal: BMC cancer

VOLUME: 8

Page Numbers: 71

Journal Abbreviation: BMC Cancer

ISSN: 1471-2407

DAY: 10

MONTH: 03

YEAR: 2008

Comprehensive analysis of NuMA variation in breast cancer. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 100967800

Comprehensive analysis of NuMA variation in breast cancer. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Comprehensive analysis of NuMA variation in breast cancer. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Comprehensive analysis of NuMA variation in breast cancer.

AFFILIATION: Department of Obstetrics and Gynecology, Helsinki University Central Hospital, Helsinki, Finland. outi.kilpivaara@helsinki.fi

Country: England

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: BMC Cancer

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Comprehensive analysis of NuMA variation in breast cancer Related Publications

• A case of foetal bleeding into maternal circulation.
• Basal cytokeratins in breast tumours among BRCA1, BRCA2 and mutation-negative breast cancer families.
• Blood transfusion and Rh immunization.
• Classification principles and genetics of chronic gastritis.
• Comprehensive analysis of NuMA variation in breast cancer.
• Haemophilia A in a girl. A probable exception from sex-linked recessive inheritance.
• Immunosuppressive therapy in Rh-incompatible transfusion.
• NAD(P)H:quinone oxidoreductase 1 NQO1*2 genotype (P187S) is a strong prognostic and predictive factor in breast cancer.
• On the factors affecting maternal Rh immunization.
• RH: serology and clinic.
• The DNA damage signalling kinase ATM is aberrantly reduced or lost in BRCA1/BRCA2-deficient and ER/PR/ERBB2-triple-negative breast cancer.
• The occurrence of kernicterus in an autopsy material.
• [A review of the activities of the Finnish Medical Association during the 1st half of 1966]
• [New regulations on specialization]
• [The doctor in the sickroom.]
• [The shortage of doctors and its correction]